{
    "code": "60001139",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001139",
    "time": "2023-09-14 22:20:19",
    "許可證字號": "衛部菌疫輸字第001139號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/10\/07",
    "發證\/登錄日期": "109\/10\/07",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000113902",
    "中文品名": "爾瑞易注射液",
    "英文品名": "Erelzi Solution for Injection",
    "適應症": "適用於對疾病緩解型抗風濕性藥物(即DMARDs，包括methotrexate ) 無適當療效之成人活動性類風濕性關節炎。\r\n也適用於先前未使用methotrexate 治療之成人中度至重度活動性類風濕性關節炎。這些病人的X光檢查顯示，etanercept可以減緩疾病造成的關節結構性受損。\r\n亦適用於methotrexate 治療無效或無法耐受的2 歲以上兒童及青少年的活動性多關節幼年型慢性關節炎。尚未對不足2 歲的兒童進行試驗。\r\n適用於對疾病緩解型抗風濕性藥物無療效之成人活動性與進行性乾癬性關節炎。\r\n治療活動性僵直性脊椎炎。\r\n適用於對其他全身性治療( 包括cyclosporine、methotrexate 或光化療法(PUVA)) 無效、有禁忌或無法耐受之中度至重度乾癬成人病人。\r\n適用於對其他全身性治療或光化療法無法有效控制或無法耐受之6 歲以上兒童及青少年的重度乾癬。",
    "劑型": "270注射劑",
    "包裝": "0.5ml及1ml預充填玻璃注射針筒；1ml預充填玻璃注射筆，100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "114\/10\/07",
    "主成分略述": "ETANERCEPT",
    "限制項目": "02輸　入 1D須執行風險管理計畫 91生物相似性藥品",
    "申請商名稱": "台灣諾華股份有限公司",
    "申請商地址": "台北市中山區民生東路三段2號8樓",
    "主製造廠": [
        {
            "製造廠名稱": "SANDOZ GMBH,  SCHAFTENAU PLANT",
            "製造廠廠址": "BIOCHEMIESTRASSE 10, A6336 LANGKAMPFEN, AUSTRIA",
            "製造廠公司地址": "",
            "製造廠國別": "AUSTRIA",
            "製程": "原料藥及成品製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200042400",
            "成分名稱": "ETANERCEPT",
            "含量描述": "",
            "含量": "50.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Erelzi-112-02-16(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "爾瑞易注射液_480x990_TWI-070122-111-02-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=002&Type=9"
        },
        {
            "title": "LB_50mg AI-110-01-27.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=011&Type=8"
        },
        {
            "title": "BL_50mg PFS-110-01-27.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=010&Type=8"
        },
        {
            "title": "BL_25mg PFS-110-01-27.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=009&Type=8"
        },
        {
            "title": "爾瑞易注射液 (PFS) 50mg_外盒-109-12-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=008&Type=8"
        },
        {
            "title": "LB_50mg PFS-109-12-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=007&Type=8"
        },
        {
            "title": "爾瑞易注射液50mg_筆型外盒-109-12-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=005&Type=8"
        },
        {
            "title": "爾瑞易注射液(PFS) 25mg_外盒-109-12-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=003&Type=8"
        },
        {
            "title": "LB_25mg PFS-109-12-30.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001139&Seq=002&Type=8"
        }
    ]
}